Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) saw a downside of -3.03% to close Tuesday at $1.28 after subtracting -$0.04 on the day. The 5-day average trading volume is 1,941,840 shares of the company’s common stock. It has gained $1.3700 in the past week and touched a new high 1 time within the past 5 days. An average of 976,365 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,171,942.
ZYNE’s 1-month performance is -3.40% or -$0.0450 on its low of $1.2700 reached on 09/26/23. The company’s shares have touched a 52-week low of $0.25 and high of $1.40, with the stock’s rally to the 52-week high happening on 09/15/23. YTD, ZYNE has achieved 141.51% or $0.7500 and has reached a new high 11 times. However, the current price is down -8.57% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
ZYNE stock investors last saw insider trading activity on Sep 13.ANIDO ARMANDO (Chairman & Chief Exec. Officer) most recently sold 17,830 shares at $1.33 per share on Sep 13. This transaction cost the insider $23,637. President, Sebree Terri B, sold 12,401 shares at a price of $1.33 on Sep 13. Then, on Sep 13, Chief Financial Officer Fickenscher James E sold 8,998 shares at a price of $1.33 per share. This transaction amounted to $11,929.
Valuation Metrics
ZYNE stock has a beta of 1.32. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 2.38.
Zynerba Pharmaceuticals Inc’s quick ratio for the period ended June 29 was 3.41, with the current ratio over the same period at 3.41.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income grew 8.63% to -$10.78 million, while revenue of -$10.11 million was 6.22% off the previous quarter. Analysts expected ZYNE to announce -$0.2 per share in earnings in its latest quarter, but it posted -$0.21, representing a -5.00% surprise. ZYNE stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 11.46 million, with total debt at $0.22 million. Shareholders hold equity totaling $53.94 million.
Let’s look briefly at Zynerba Pharmaceuticals Inc (ZYNE) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 26 September was 43.51% to suggest the stock is trending Neutral, with historical volatility in this time period at 34.57%.
The stock’s 5-day moving average is $1.3260, reflecting a -3.76% or -$0.0500 change from its current price. ZYNE is currently trading -3.03% above its 20-day SMA, +250.88% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +265.71% and SMA200 by+120.69%.
Stochastic %K and %D was 17.38% and 26.78% and the average true range (ATR) pointed at 0.0403. The RSI (14) points at 58.23%, while the 14-day stochastic is at 7.69% with the period’s ATR at 0.0423. The stock’s 9-day MACD Oscillator is pointing at -0.0233 and -0.0188 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), H.C. Wainwright reiterated its a Buy rating for the company but lifted their price target by $12 to $9. Analysts offering their rating for ZYNE stock have a consensus rating for the stock as Hold. Currently, 0 brokerage advisors rate ZYNE as a “sell,”, while 4 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 0 have offered a “buy” rating.
What is ZYNE’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $1.11 and a high of $1.40, with their median price target at $1.25. Looking at these predictions, the average price target given by analysts is for Zynerba Pharmaceuticals Inc (ZYNE) stock is $1.25.
